Akebia Therapeutics (AKBA) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to -$166.4 million.
- Akebia Therapeutics' Enterprise Value fell 38926.78% to -$166.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$166.4 million, marking a year-over-year decrease of 38926.78%. This contributed to the annual value of -$51.9 million for FY2024, which is 2083.87% down from last year.
- Latest data reveals that Akebia Therapeutics reported Enterprise Value of -$166.4 million as of Q3 2025, which was down 38926.78% from -$137.3 million recorded in Q2 2025.
- Akebia Therapeutics' Enterprise Value's 5-year high stood at -$34.0 million during Q3 2024, with a 5-year trough of -$252.8 million in Q1 2021.
- Over the past 5 years, Akebia Therapeutics' median Enterprise Value value was -$113.4 million (recorded in 2025), while the average stood at -$115.5 million.
- Per our database at Business Quant, Akebia Therapeutics' Enterprise Value soared by 6786.67% in 2023 and then crashed by 38926.78% in 2025.
- Akebia Therapeutics' Enterprise Value (Quarter) stood at -$149.8 million in 2021, then surged by 39.61% to -$90.5 million in 2022, then skyrocketed by 52.55% to -$42.9 million in 2023, then decreased by 20.84% to -$51.9 million in 2024, then crashed by 220.89% to -$166.4 million in 2025.
- Its Enterprise Value was -$166.4 million in Q3 2025, compared to -$137.3 million in Q2 2025 and -$113.4 million in Q1 2025.